Re-irradiation in conjunction with liposomal doxorubicin for the treatment of skin metastases of recurrent breast cancer: a radiobiological approach and 2 year of follow-up.
Thirty patients with local relapses after radical mastectomy and radiotherapy and undergoing infusion of liposomal doxorubicin (40 mg/m(2) monthly for 6 months) were randomized to receive re-irradiation. Radiotherapy was with either 17 fractions of 1.8 Gy, 5 days a week (N=15, group A) or 4 Gy plus two fractions of 3 Gy the 1st week and six fractions of 3 Gy given every second day (N=15, group B). Eight patients from group A (53.3%) and nine patients (60%) from group B demonstrating a clinically complete response (P=0.9). Grade I/II acute skin toxicity was monitored in 26.6% of patients in group A versus 73.3% in group B. The radiation schedule of group A seems superior for grade I/II acute (P=0.027) and late (P=0.015) skin toxicity. The linear quadratic model enabled the prediction of tumor response as well as normal skin reactions.
Kouloulias
Vassilis E
VE
Radiotherapy Department, Areteion University Hospital, Vas. Sofias Avenue 76, Athens, Greece. vko@eortc.be
Plataniotis
George A
GA
Kouvaris
John R
JR
Dardoufas
Costas E
CE
Gennatas
Costas
C
Landuyt
Willy
W
Pistevou-Gompaki
Kiki
K
Vlahos
Lambros J
LJ
D000970:Antineoplastic Agents / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D004317:Doxorubicin / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D009362:Neoplasm Metastasis; D012307:Risk Factors; D012867:Skin / Q000528:radiation effects; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D013997:Time Factors
D000970:Antineoplastic Agents; D004317:Doxorubicin